Product Description
Eravacycline (Xerava™), a novel fully synthetic fluorocycline, consists of the tetracyclic core scaffold with unique modifications in the tetracyclic D ring; consequently, it exhibits potent in vitro activity against Gram-positive and -negative bacterial strains expressing certain common tetracycline-specific acquired resistance mechanisms. In vitro, eravacycline exhibits potent activity against a broad spectrum of clinically relevant Gram-positive and -negative aerobic and anaerobic bacteria. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505493/)
Mechanisms of Action: 30S Ribosomal Subunit Antagonist,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hong Kong | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | Poland | Portugal | Romania | Singapore | Slovakia | Slovenia | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Communicable Diseases|Intraabdominal Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CS434-2023-001 | P2 |
Recruiting |
Intraabdominal Infections|Communicable Diseases |
2026-02-02 |